Blueprint Medicines announced data from their registration-enabling NAVIGATOR trial of avapritinib in patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST.   These results were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting and will form the basis for planned worldwide marketing applications for avapritinib. The data demonstrate clinical activity […]

GIST SUPPORT UK is a member of Cancer52 who are an alliance of nearly 100 rare cancer groups. Cancer52 members have been approached by the research team at the Sir William Dunn School of Pathology, University of Oxford, who are working on a European funded rare cancer initiative that seeks to find and develop innovative solutions to […]

GIST patient advocates from the global GIST patient community came together, to interact with top GIST experts, to have access to state-of-the- art medical and scientific information and to exchange best practice in patient advocacy among each other. The 2018 conference was balanced symbiosis of medical content, advocacy topics and capacity building sessions. NHGIST_2018_Conference-Report_RL_D (3)

A big thank you to Scotmid Co-operative for choosing to support GIST Support UK and the development of our National GIST Tissue bank. Scotmid Co-operative are pleased to support GIST Support UK with a donation designed to help find improved treatment for all forms of this rare cancer. GastroIntestinal Stromal Tumours affects both adults and children with approximately 900 new patients […]

NEWS RELEASE Cancer Charity GIST Support UK celebrate the NICE Approval of Regorafenib for GIST Cancer Patients Today GIST Support UK, the key charity specifically focused on combating GIST  (gastrointestinal stromal tumour), celebrated the NICE decision to approve regorafenib, a life extending drug, as a third line treatment for GIST cancer patients in England, ensuring […]

On 19th August the Times published an article on page 19 entitled: This article by science correspondent Oliver Moody reports on the remarkable impact that Imatinib (Glivec) has had on the lives of many GIST patients and features quotes from our Medical Advisory Board Chair Professor Ian Judson and his colleague Professor Winette van der […]

We are delighted to announce that the National GIST guidelines have been updated by the British Sarcoma Group GIST specialists and are now published. A copy of the latest guidelines can be viewed here.

GSUK’s Chair Nic Puntis discusses the BBC’s report on the Cancer Drugs Fund on BBC Wiltshire Radio – listen below…